Literature DB >> 27154986

Residual mucin and response after neoadjuvant chemotherapy (NAC) in breast cancer.

Maria Jove1, Eldo Verghese2, Nisha Sharma3, Sally Lane2.   

Abstract

Neoadjuvant chemotherapy (NAC) is the standard of care for patients with breast cancer with inoperable disease or smaller tumours who might benefit from a conservative surgery after downstaging of their disease. Nevertheless, evidence shows that preoperative and postoperative chemotherapy are equivalent in terms of long-term survival. Response and histological changes after NAC have been widely studied in invasive ductal carcinoma not otherwise specified, but there is a paucity of characterisation of patterns of response to chemotherapy in less frequent histological types. We report extensive residual mucin deposits after chemotherapy in a woman with locally advanced breast cancer and a prominent mucinous component at diagnosis. Interestingly, residual mucin was co-located with the initial tumour, in the breast as well as in the axillary lymph nodes. The distribution of mucin may be a valuable marker of the extent of mucinous carcinomas prior to NAC. 2016 BMJ Publishing Group Ltd.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27154986      PMCID: PMC4885263          DOI: 10.1136/bcr-2016-214509

Source DB:  PubMed          Journal:  BMJ Case Rep        ISSN: 1757-790X


  15 in total

1.  Mucinous breast carcinoma: a large contemporary series.

Authors:  Christina R Barkley; Jennifer A Ligibel; Julia S Wong; Stuart Lipsitz; Barbara L Smith; Mehra Golshan
Journal:  Am J Surg       Date:  2008-10       Impact factor: 2.565

2.  Pure and mixed mucinous carcinomas of the breast: a clinicopathologic analysis of 61 cases with long-term follow-up.

Authors:  S Toikkanen; H Kujari
Journal:  Hum Pathol       Date:  1989-08       Impact factor: 3.466

Review 3.  Breast carcinoma--rare types: review of the literature.

Authors:  R Yerushalmi; M M Hayes; K A Gelmon
Journal:  Ann Oncol       Date:  2009-07-14       Impact factor: 32.976

4.  Histopathologic changes following neoadjuvant chemotherapy in locally advanced breast cancer.

Authors:  D Sethi; R Sen; S Parshad; S Khetarpal; M Garg; J Sen
Journal:  Indian J Cancer       Date:  2013 Jan-Mar       Impact factor: 1.224

5.  Do clinical and immunohistochemical findings of pure mucinous breast carcinoma differ from mixed mucinous breast carcinoma?

Authors:  Y Erhan; M Ciris; O Zekioglu; Y Erhan; M Kapkac; O Makay; N Ozdemir
Journal:  Acta Chir Belg       Date:  2009 Mar-Apr       Impact factor: 1.090

6.  A retrospective review with long term follow up of 11,400 cases of pure mucinous breast carcinoma.

Authors:  Salomone Di Saverio; Juan Gutierrez; Eli Avisar
Journal:  Breast Cancer Res Treat       Date:  2007-11-18       Impact factor: 4.872

Review 7.  Pathology of breast carcinomas after neoadjuvant chemotherapy: an overview with recommendations on specimen processing and reporting.

Authors:  Sunati Sahoo; Susan C Lester
Journal:  Arch Pathol Lab Med       Date:  2009-04       Impact factor: 5.534

8.  Impact of acellular mucin pools on survival in patients with complete pathological response to neoadjuvant treatment in rectal cancer.

Authors:  Abu Bakar Hafeez Bhatti; Ali Akbar; Shahid Khattak; Ather Saeed Kazmi; Aarif Jamshed; Aamir Ali Syed
Journal:  Int J Surg       Date:  2014-07-27       Impact factor: 6.071

9.  Mucinous carcinoma of the breast is genomically distinct from invasive ductal carcinomas of no special type.

Authors:  Magali Lacroix-Triki; Paula H Suarez; Alan MacKay; Maryou B Lambros; Rachael Natrajan; Kay Savage; Felipe C Geyer; Britta Weigelt; Alan Ashworth; Jorge S Reis-Filho
Journal:  J Pathol       Date:  2010-11       Impact factor: 7.996

10.  Pure mucinous carcinoma of the breast: clinicopathologic characteristics and long-term outcome among Taiwanese women.

Authors:  Hsin-Shun Tseng; Che Lin; Szu-Erh Chan; Su-Yu Chien; Shou-Jen Kuo; Shou-Tung Chen; Tsai-Wang Chang; Dar-Ren Chen
Journal:  World J Surg Oncol       Date:  2013-06-14       Impact factor: 2.754

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.